title: Frequency of TP53 Mutations and its Impact on Drug Sensitivity in Acute Myeloid Leukemia?
abstract: The purpose of this study is to find out the frequency of TP53 mutations in acute myeloid leukemia (AML) patients and correlate sensitivity of drug response with TP53 mutations. In AML more than 90 % of cases comprise of wild type TP53. 94.2 % of TP53 mutations are found within exon 5-8 of which 73 % are point mutations. TP53 mutations were analysed with high resolution melting curve analysis. We analysed 106 AML samples of which we found nine mutations which represents 8.5 % mutation rate and found one rare SNP. The effect of TP53 mutations were studied on the chemosensitivity of two new drugs AZD115 and RHPS4, an Aurora Kinase B inhibitor and Telomerase inhibitor respectively. Four mutations were found out of 17 for RHPS4 stating significant (p = 0.002) increase in sensitivity and no mutation found in AZD1152 database, but need more study to get definite conclusion.
authors.affiliation: Department of Molecular Medical Sciences, Queens Medical Centre, University of Nottingham, Nottingham, NG7 2UH UK.
authors.forename: Ankur
authors.initials: A
authors.lastname: Shah
authors.forename: Claire
authors.initials: C
authors.lastname: Seedhouse
keywords: Acute myeloid leukemia; Drug sensitivity; High resolution melting curve analysis; TP53
references.citation: Leukemia. 1993 Apr;7(4):593-600
references.pmid: 8464238
references.citation: Proc Natl Acad Sci U S A. 1991 Jun 15;88(12):5413-7
references.pmid: 2052620
references.citation: Blood. 2007 Sep 15;110(6):2034-40
references.pmid: 17495131
references.citation: Cancer Res. 2000 Dec 15;60(24):6788-93
references.pmid: 11156366
references.citation: BMC Genet. 2009 Feb 17;10:5
references.pmid: 19222838
references.citation: J Mol Diagn. 2005 Aug;7(3):413-21
references.pmid: 16049314
references.citation: J Clin Invest. 2007 Nov;117(11):3236-47
references.pmid: 17932567
references.citation: EMBO J. 1991 Oct;10(10):2879-87
references.pmid: 1915267
references.citation: BMC Cancer. 2006 Dec 21;6:295
references.pmid: 17184525
references.citation: Br J Cancer. 2006 Jan 30;94(2):318-22
references.pmid: 16421597
references.citation: Blood. 1992 May 1;79(9):2378-83
references.pmid: 1571549
references.citation: Fukuoka Igaku Zasshi. 2009 Jun;100(6):217-28
references.pmid: 19670804
references.citation: Clin Chem. 2004 Oct;50(10):1748-54
references.pmid: 15308590
references.citation: Int J Hematol. 2010 Jan;91(1):69-77
references.pmid: 20013323
references.citation: Nature. 1989 Dec 7;342(6250):705-8
references.pmid: 2531845
references.citation: Clin Chem. 2004 Jul;50(7):1156-64
references.pmid: 15229148
references.citation: Hematology Am Soc Hematol Educ Program. 2009;:385-95
references.pmid: 20008224
references.citation: Eur J Cancer. 2006 Aug;42(12):1881-8
references.pmid: 16750909
references.citation: Cell Cycle. 2009 Jun 15;8(12):1921-9
references.pmid: 19440047
references.citation: Leukemia. 2008 Aug;22(8):1539-41
references.pmid: 18528419
references.citation: Cell Cycle. 2009 Oct 1;8(19):3172-81
references.pmid: 19755861
references.citation: Mol Cancer Ther. 2010 Mar;9(3):661-72
references.pmid: 20159992
references.citation: PLoS One. 2011 Jan 17;6(1):e14522
references.pmid: 21264207
references.citation: BMC Cancer. 2007 Aug 31;7:168
references.pmid: 17764544
references.citation: Nucleic Acids Res. 2009 Sep;37(16):5353-64
references.pmid: 19596811